Join Our Mailing List.
Receive monthly insights and important updates delivered straight from our consultants to
your inbox.
Rejecting a Psychedelic Drug for PTSD Treatment: Why and What’s Next
Sep 04, 2024
Natalie Emerson
1 min
Share
A revolution in the use of psychedelic drugs to treat mental health issues experienced a setback in early August when the FDA declined to approve MMDA as a treatment for post-traumatic stress disorder.
Host Stephanie Kennan provides important context to the FDA’s decision, which came as the agency has faced criticism for approving therapies without convincing evidence. She outlines the fallout, including a peer-reviewed journal’s decision to retract three papers about MMDA-assisted psychotherapy. She also looks ahead, explaining that, while this first attempt for MMDA stalled, other companies are working on their own applications.
Episode 33: August 29, 2024
Click follow for links to all podcast platforms.
Categories:
Insights